Cytoreductive nephrectomy (CRN) has long been considered a standard of care in metastatic renal cell carcinoma; however, it still poses major therapeutic challenges with respect to patient factors, the timing of surgery, and its combination with other therapies. With the advent of targeted therapies, the role of CRN has been questioned as several retrospective analyses have shown potential benefits, particularly in the case of intermediate-risk diseases. While CRN may benefit some subgroups, it is no longer the standard of care for patients with metastatic renal cell carcinoma.
In this era of immunotherapy, the role of CRN must evolve to be able to offer surgical interventions with minimal delay in systemic treatment. For more insights on the diagnosis, prognosis, and management of renal cancers, join Dr. Saurabh Patil for an exclusive session on “ Role of Cytoreductive Nephrectomy in…
